Storia in 3 fonti

FDA Greenlights Next-Generation ROS1 Inhibitor for Lung Cancer

Zidesamtinib is indicated for patients who received a prior ROS1 inhibitor

Raccontata da

medpagetoday.com

benzinga.com

healio.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo2 g fa

FDA Greenlights Next-Generation ROS1 Inhibitor for Lung Cancer

Zidesamtinib is indicated for patients who received a prior ROS1 inhibitor

originale

healio.com1 g fa

Jideytro nabs FDA approval as second-line treatment in non-small cell lung cancer

The FDA has approved zidesamtinib for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer.Zidesamtinib (Jideytro, GSK) is designed to provide highly selective coverage of ROS1 mutations…

Leggi questa versione → originale

Timeline cronologica

mercoledì 22 luglio 2026·medpagetoday.com
FDA Greenlights Next-Generation ROS1 Inhibitor for Lung Cancer
Zidesamtinib is indicated for patients who received a prior ROS1 inhibitor
mercoledì 22 luglio 2026·benzinga.com
FDA Greenlights GSK’s First Lung Cancer Drug Ahead of Schedule - GSK (NYSE:GSK)
GSK wins early FDA approval for Jideytro, a targeted treatment for adults with advanced ROS1-positive non-small cell lung cancer.

FDA Greenlights Next-Generation ROS1 Inhibitor for Lung Cancer

Jideytro nabs FDA approval as second-line treatment in non-small cell lung cancer

Timeline cronologica

FDA Greenlights Next-Generation ROS1 Inhibitor for Lung Cancer

FDA Greenlights GSK’s First Lung Cancer Drug Ahead of Schedule - GSK (NYSE:GSK)

FDA Greenlights GSK’s First Lung Cancer Drug Ahead of Schedule - GSK (NYSE:GSK)

Jideytro nabs FDA approval as second-line treatment in non-small cell lung cancer